Key points
- A synthetic 15-amino-acid sequence derived from a protein found in gastric juice
- Preclinical interest centres on angiogenesis, nitric oxide signalling and growth factor pathways
- Unusually stable in aqueous solution compared with many research peptides
- Evidence is overwhelmingly animal-model; human clinical data remains limited
What BPC-157 is
Body Protection Compound-157 is a synthetic pentadecapeptide — a chain of fifteen amino acids — whose sequence corresponds to a partial fragment of a protein identified in human gastric juice. It does not occur in nature in this isolated form; the research compound is produced synthetically.
Its most-cited practical characteristic is stability. Many research peptides degrade rapidly in aqueous solution or under mildly acidic conditions, which complicates experimental design. BPC-157 has been reported to remain comparatively stable, which is part of why it appears so frequently in the preclinical literature.
The nitric oxide pathway
The most consistently reported mechanism in BPC-157 research involves the nitric oxide system. Nitric oxide is a signalling molecule central to vascular tone, blood flow regulation and endothelial behaviour, and studies have examined whether BPC-157 modulates its production and downstream effects.
This matters for tissue repair research because perfusion is often the limiting factor in how a damaged tissue recovers. Work in this area has explored whether the compound's observed effects in injury models are mediated through this pathway rather than through direct action on the tissue itself.
The mechanism is plausible and repeatedly reported, but it should be read as an active area of investigation rather than a settled account.
Angiogenesis and growth factor signalling
A second strand of research examines angiogenesis — the formation of new blood vessels from existing vasculature. Studies have looked at whether BPC-157 influences vascular endothelial growth factor signalling and related pathways involved in the vascular response to injury.
Related work has investigated interactions with growth hormone receptor expression in fibroblasts, cells central to the deposition of connective tissue during repair. The proposed picture is one of upregulated receptor sensitivity rather than direct hormone-like activity.
What the evidence base actually looks like
The literature is dominated by rodent models. Studies commonly involve controlled injury to tendon, muscle, gastrointestinal or neural tissue, with comparison against untreated controls. Reported effects have been broad enough across tissue types that some researchers have questioned whether a single mechanism can account for them.
Human clinical data is sparse. Any researcher framing a study around BPC-157 should treat the animal literature as hypothesis-generating rather than as established human pharmacology, and design accordingly.
It is also worth noting a publication concentration effect: a substantial proportion of the preclinical work originates from a relatively small number of research groups. This is not itself a criticism, but independent replication is a reasonable thing to look for when assessing the strength of any given finding.
Handling in the laboratory
BPC-157 is supplied as a lyophilized powder. Standard practice for lyophilized research peptides applies: store the sealed vial cold and protected from light, reconstitute with bacteriostatic water, and keep the reconstituted solution refrigerated.
Repeated freeze-thaw cycling is the most common avoidable cause of degradation in peptide research. Aliquoting after reconstitution avoids subjecting the whole vial to it. See our storage and handling guide for the general protocol.
For laboratory research use only. This article summarises published research for scientific reference. It is not guidance for human or veterinary use, and nothing here describes a treatment for any condition. NexPep compounds are supplied strictly for laboratory research.